Screening for hepatitis B virus to prevent viral reactivation - who and when?
作者信息
Etzion Ohad, Ghany Marc G
机构信息
Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda MD.
出版信息
Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):47-50. doi: 10.1002/cld.458. eCollection 2015 Feb.
Abstract
摘要
相似文献
1
Screening for hepatitis B virus to prevent viral reactivation - who and when?筛查乙型肝炎病毒以预防病毒再激活——对象和时机？
Clin Liver Dis (Hoboken). 2015 Mar 27;5(2):47-50. doi: 10.1002/cld.458. eCollection 2015 Feb.
2
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Introduction and Immunology.筛查和预防乙型肝炎再激活：介绍和免疫学。
Clin Liver Dis. 2019 Aug;23(3):487-492. doi: 10.1016/j.cld.2019.04.009. Epub 2019 Jun 6.
3
Use of famciclovir to prevent HBV reactivation in HBsAg-positive recipients after allogeneic bone marrow transplantation.使用泛昔洛韦预防异基因骨髓移植后HBsAg阳性受者的HBV再激活。
J Hepatol. 1998 Mar;28(3):359-68. doi: 10.1016/s0168-8278(98)80307-3.
4
[Hepatitis B virus reactivation in patients infected with HIV].[感染人类免疫缺陷病毒患者的乙型肝炎病毒再激活]
Bacteriol Virusol Parazitol Epidemiol. 1997 Jan-Jun;42(1-2):59-63.
5
Kinetics of viral loads and risk of hepatitis B virus reactivation in hepatitis B core antibody-positive rheumatoid arthritis patients undergoing anti-tumour necrosis factor alpha therapy.HBV 核心抗体阳性的类风湿关节炎患者接受抗 TNF-α 治疗时病毒载量的动力学变化及乙型肝炎病毒再激活的风险。
Ann Rheum Dis. 2011 Oct;70(10):1719-25. doi: 10.1136/ard.2010.148783. Epub 2011 Jun 29.
6
Management of chemotherapy-induced hepatitis B virus reactivation.化疗诱导乙型肝炎病毒再激活的管理。
J Chin Med Assoc. 2012 Aug;75(8):359-62. doi: 10.1016/j.jcma.2012.06.006. Epub 2012 Jul 21.
7
Reactivation of hepatitis B virus associated with chemotherapy and immunosuppressive agent.与化疗和免疫抑制剂相关的乙型肝炎病毒再激活
Acta Med Indones. 2013 Jan;45(1):61-6.
8
Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.接受抗癌治疗的血液系统恶性肿瘤患者中乙型肝炎病毒再激活的预防与管理
World J Gastroenterol. 2016 Jul 28;22(28):6484-500. doi: 10.3748/wjg.v22.i28.6484.
9
Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Patients with Hematological and Solid Tumor Malignancies.筛查和预防乙型肝炎病毒再激活：血液系统和实体肿瘤恶性肿瘤患者。
Clin Liver Dis. 2019 Aug;23(3):511-519. doi: 10.1016/j.cld.2019.04.011. Epub 2019 Jun 6.
10
High titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma.高滴度抗-HBs 可预防已缓解乙型肝炎患者非霍奇金淋巴瘤患者接受利妥昔单抗治疗相关的病毒再激活。
J Med Virol. 2016 Jun;88(6):1010-7. doi: 10.1002/jmv.24423. Epub 2015 Nov 13.
引用本文的文献
1
Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study.一项随机前瞻性研究，评估替诺福韦酯富马酸盐对接受基于利妥昔单抗方案治疗血液系统恶性肿瘤的抗-HBc阳性患者预防乙型肝炎病毒再激活的作用：Preblin研究。
PLoS One. 2017 Sep 12;12(9):e0184550. doi: 10.1371/journal.pone.0184550. eCollection 2017.
2
Management of hepatitis B reactivation in immunosuppressed patients: An update on current recommendations.免疫抑制患者中乙肝再激活的管理：当前推荐的最新进展。
World J Hepatol. 2016 Mar 18;8(8):385-94. doi: 10.4254/wjh.v8.i8.385.
本文引用的文献
1
Computerized physician order entry-based system to prevent HBV reactivation in patients treated with biologic agents: the PRESCRIB project.基于计算机的医师医嘱输入系统预防生物制剂治疗患者的 HBV 再激活：PRESCRIB 项目。
Hepatology. 2014 Jul;60(1):106-13. doi: 10.1002/hep.27103. Epub 2014 May 28.
2
Immunosuppression and HBV reactivation.免疫抑制和 HBV 再激活。
Semin Liver Dis. 2013 May;33(2):167-77. doi: 10.1055/s-0033-1345722. Epub 2013 Jun 8.
3
Low rates of hepatitis B virus screening at the onset of chemotherapy.化疗起始时乙型肝炎病毒筛查率较低。
J Oncol Pract. 2012 Jul;8(4):e32-9. doi: 10.1200/JOP.2011.000450. Epub 2012 Jun 12.
4
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.欧洲肝脏研究学会临床实践指南：慢性乙型肝炎病毒感染的管理
J Hepatol. 2012 Jul;57(1):167-85. doi: 10.1016/j.jhep.2012.02.010. Epub 2012 Mar 20.
5
The increasing burden of imported chronic hepatitis B--United States, 1974-2008.慢性乙型肝炎输入性负担日益加重——美国，1974-2008 年。
PLoS One. 2011;6(12):e27717. doi: 10.1371/journal.pone.0027717. Epub 2011 Dec 7.
6
Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.接受肿瘤坏死因子（TNF）靶向治疗患者的乙型肝炎病毒（HBV）再激活：257例分析
Medicine (Baltimore). 2011 Nov;90(6):359-371. doi: 10.1097/MD.0b013e3182380a76.
7
Why, when, and how to prevent hepatitis B virus reactivation in cancer patients undergoing chemotherapy.为什么、何时以及如何预防癌症患者化疗期间乙型肝炎病毒再激活。
J Natl Compr Canc Netw. 2011 May;9(5):465-77. doi: 10.6004/jnccn.2011.0045.
8
American Society of Clinical Oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases.美国临床肿瘤学会临时临床意见：恶性疾病治疗中接受细胞毒性化疗患者的慢性乙型肝炎病毒感染筛查。
J Clin Oncol. 2010 Jul 1;28(19):3199-202. doi: 10.1200/JCO.2010.30.0673. Epub 2010 Jun 1.
9
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update.亚太地区慢性乙型肝炎管理共识声明：2008 年更新版。
Hepatol Int. 2008 Sep;2(3):263-83. doi: 10.1007/s12072-008-9080-3. Epub 2008 May 10.
10
Recommendations for identification and public health management of persons with chronic hepatitis B virus infection.慢性乙型肝炎病毒感染者的识别及公共卫生管理建议
MMWR Recomm Rep. 2008 Sep 19;57(RR-8):1-20.
Zotero 插件